This discovery underscores the potential of MET-targeted therapies and establishes a robust scientific rationale for the implementation of combination strategies or novel approaches, such as CAR-T cell therapy, in the treatment of NSCLC. The gene discussed is MET; the disease is non-small cell lung carcinoma.